Neuropeptide Y and derivates are not ready for prime time in prostate cancer early detection
Neuropeptide Y (NPY) and related peptides have been proposed as promising biomarkers for the diagnosis of prostate cancer by previous immunoassays and immunohistochemical studies. In this study, we evaluated the additional value of NPY and related peptides compared with prostate-specific antigen (PS...
Asıl Yazarlar: | Maurer, J, Eugster, PJ, Collins, K, Vocat, C, Oke, J, Nicholson, B, Rakauskas, A, Grouzmann, E, Valerio, M |
---|---|
Materyal Türü: | Journal article |
Dil: | English |
Baskı/Yayın Bilgisi: |
Elsevier
2024
|
Benzer Materyaller
-
Neuropeptide Y and Derivates Are Not Ready for Prime Time in Prostate Cancer Early Detection
Yazar:: Jonathan Maurer, ve diğerleri
Baskı/Yayın Bilgisi: (2024-08-01) -
Genomic Testing for Advanced Prostate Cancer: Ready for Prime Time?
Yazar:: Alexander Meisel
Baskı/Yayın Bilgisi: (2019-12-01) -
Saxagliptin: A potential doping agent? A randomized, double‐blinded, placebo‐controlled, and crossover pilot study in young active men
Yazar:: Nicolas Bourdillon, ve diğerleri
Baskı/Yayın Bilgisi: (2022-12-01) -
Biomarkers in early-stage colorectal cancer: ready for prime time?
Yazar:: Church, D, ve diğerleri
Baskı/Yayın Bilgisi: (2012) -
REBOA: is it ready for prime time?
Yazar:: Jay Doucet, ve diğerleri